Zepbound clocked in sales of US$3.38-billion for the quarter. Analysts were expecting sales of US$2.95-billion. Share Save for later Please log in to bookmark this story. Log In Create Free Account

Eli Lilly and Company LLY-N raised its full-year profit and sales forecast on Thursday, betting on surging demand for its blockbuster weight-loss drug, Zepbound, as it targets new markets and looks to grab more share from Novo Nordisk’s Wegovy.

However, shares of the U.S. drugmaker fell over 10 per cent to US$671.54 in premarket trading after data from its oral weight loss drug, orforglipron, disappointed investors.

Orforglipron helped patients lose 12.4 per cent of their weight on average after 72 weeks, less than the 14.9 per cent weight loss seen in a previous tria

See Full Page